Phase II Open-Label, Single-Center Study Evaluating Safety and Efficacy of Pembrolizumab Following Induction with the Hypomethylating Agent Azacitidine in Patients with Advanced Pancreatic Cancer After Failure of First-Line Therapy.

Protocol: 
AAAR3554
Phase: 
II

Phase II Open-Label, Single-Center Study Evaluating Safety and Efficacy of Pembrolizumab Following Induction with the Hypomethylating Agent Azacitidine in Patients with Advanced Pancreatic Cancer After Failure of First-Line Therapy.

The purpose of this study is to determine the effectiveness of combining immune therapy with a hypomethylating agent for pancreatic cancer. People who have advanced pancreatic cancer with disease progression on first-line therapy are usually treated with a second chemotherapy regimen. However, there is no single accepted chemotherapy regimen and national guidelines recommend chemotherapy or clinical trial participation. In this study, all study subjects will receive a combination of immune therapy (every 3 weeks) and a hypomethylating agent (every 4 weeks).

Are you Eligible? (Inclusion Criteria)

1)Age ≥18 years of age on day of signing informed consent.

? 2)Have a performance status of 0 or 1 using the ECOG Performance Scale within 3 days of first dose of study drug.

3)? Have a predicted life expectancy of greater than 3 months.

4) Confirmed diagnosis of pancreatic ductal adenocarcinoma through cell tissue diagnoses.

Specialty Area(s)

Immunotherapy

Trial Location

Herbert Irving Comprehensive Cancer Center
161 Fort Washington Ave.
Herbert Irving Pavilion
New York, NY 10032
United States